Although estrogen is known to protect against -amyloid (A )-induced neurotoxicity, the mechanisms responsible for this effect are only beginning to be elucidated. In addition, the effect of raloxifene on A -induced neurotoxicity remains unknown. Here we investigated whether raloxifene exhibits similar neuro-protective effects to estrogen against A -induced neurotoxicity and the mechanism of the effects of these agents in PC12 cells transfected with the full-length human estrogen receptor (ER) gene (PCER). Raloxifene, like 17 -estradiol (E 2 ), significantly inhibited A -induced apoptosis in PCER cells, but not in a control line of cells transfected with vector DNA alone (PCCON). Since telomerase activity, the level of which is modulated by regulation of telomerase catalytic subunit (TERT) at both the transcriptional and posttranscriptional levels, is known to be involved in suppressing apoptosis in neurons, we examined the effect of E 2 and raloxifene on telomerase activity. Although both E 2 and raloxifene induced telomerase activity in PCER cells, but not in PCCON cells, treated with A , they had no effect on the level of TERT expression. These results suggest that neither E 2 nor raloxifene affects the telomerase activity at the transcriptional level. We therefore studied the mechanism by which E 2 and raloxifene induce the telomerase activity at the post-transcriptional level. Both E 2 and raloxifene induced the phosphorylation of Akt, and pretreatment with a phosphatidylinositol 3-kinase inhibitor, LY294002, attenuated both E 2 -and raloxifene-induced activation of the telomerase activity. Moreover, both E 2 and raloxifene induced both the phosphorylation of TERT at a putative Akt phosphorylation site and the association of nuclear factor B with TERT. Our findings suggest that E 2 and raloxifene exert neuroprotective effects by telomerase activation via a post-transcriptional cascade in an experimental model relevant to Alzheimer's disease.
Introduction
Alzheimer's disease (AD) is one of the most common neuro-degenerative diseases and is the most frequent cause of dementia in the elderly (Bondi et al. 1995) . However, the cause of AD is still unknown and the treatment is therefore only palliative. Compared with men, women appear to be at an increased risk for AD after age 80 to 85 years (Miech et al. 2002 , Zandi et al. 2002 . Postmenopausal depletion of endogenous estrogens may contribute to this risk. Several clinical trials have shown that women who received estrogen replacement therapy had a reduced risk of developing AD (Tang et al. 1996 , Kawas et al. 1997 , Paganini-Hill & Henderson 1996 . Estrogens may exert several neuroprotective effects on the aging brain, including inhibition of -amyloid (A ) formation, stimulation of cholinergic activity, reduction of oxidative stress-related cell damage, and protection against vascular risks (Skoog & Gustafson 1999) . However, the precise mechanism of the neuroprotective mechanism of estrogen has not been elucidated.
Although estrogen replacement therapy is widely prescribed, it may have certain disadvantages because it has been shown to be associated with an increased risk of developing breast and uterine cancers. Thus, because of the need to circumvent the limitations of estrogen replacement therapy, there has been intense interest in the therapeutic use of nonsteroidal selective estrogen receptor modulators (SERMs). Raloxifene, which has been classified as a SERM, produces both estrogen-agonistic effects on the bone and lipid metabolism and estrogenantagonistic effects on the uterine endometrium and breast tissue (Delmas et al. 1997 , Cummings et al. 1999 , Ettinger et al. 1999 . Although raloxifene is known to induce neurite outgrowth in estrogen receptor (ER)-positive PC12 cells (Nilsen et al. 1998) , the mechanism of neuroprotection by raloxifene has also not been clearly resolved.
Telomerase is a cellular reverse transcriptase that catalyzes the synthesis and extension of telomeric DNA (Greider & Blackburn 1985 , 1989 ). This enzyme is specifically activated in most malignant tumors but is usually inactive in normal somatic cells, with the result that the ends of chromosomes (telomeres) are progressively shortened during maturation and aging (Kim et al. 1994 , Shay & Bacchetti 1997 . Cells require a mechanism to maintain telomere stability in order to overcome replicative senescence, and telomerase activation may therefore be a rate-limiting or critical step in cellular immortality and oncogenesis (Harley & Villeponteau 1995) . Telomerase consists of an RNA subunit and a protein called the catalytic subunit of telomerase (TERT). Although the RNA subunit of the telomerase complex is constitutively expressed in both tumor and normal somatic tissues, the expression of TERT correlates with telomerase activity during cellular differentiation and neoplastic transformation (Kilian et al. 1997 , Meyerson et al. 1997 , Nakamura et al. 1997 . It was recently reported that TERT protects neurons against A - (Zhu et al. 2000) or tropic factor withdrawal-and glutamate (Fu et al. 2000 )-induced apoptosis.
There is abundant evidence supporting the idea that the regulation of telomerase in mammalian cells is multifactorial. Telomerase activity can be regulated by modulating both the expression and phosphorylation of TERT. The region surrounding Ser-824 in human (h) TERT conforms to a consensus sequence for phosphorylation by Akt, and Akt kinase enhances the human telomerase activity through phosphorylation of hTERT (Kang et al. 1999) . In addition, it was recently reported that estrogen protects against A - (Zhang et al. 2001) or glutamate (Honda et al. 2000) -induced neurotoxicity via the activation of Akt. Moreover, pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism (Breitschopf et al. 2001 ) and we have reported that both estrogen (Hisamoto et al. 2001a ) and raloxifene (Hisamoto et al. 2001b ) induce endothelial nitric oxide synthase (eNOS) activation via an Akt cascade. Thus, it appears possible that estrogen and raloxifene exert neuroprotective effects by enhancing the human telomerase activity through an Akt cascade.
These findings led us to examine whether raloxifene has a neuroprotective function, as estrogen does, and whether the effects are induced by enhancing human telomerase activity through an Akt cascade. Synthetic A (human, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , the cytotoxic sequence between amino acid residues 25 and 35 A , was purchased from Peptide Institute (Osaka, Japan). LipofectAMINE Plus reagent and G418 (geneticin) were purchased from Invitrogen (Carlsbad, CA, USA). Raloxifene analog, LY117018, was a kind gift from Eli Lilly Research Laboratories (Indianapolis, IN, USA). 17 -estradiol (E 2 ), dimethyl sulfoxide (DMSO), and rabbit IgG (immunoglobulin G) were purchased from Sigma. LY294002 was purchased from Calbiochem (San Diego, CA, USA). The anti-phospho-Akt, phospho-Akt substrate, and Akt were obtained from Cell Signaling (Beverly, MA, USA). The anti-nuclear factor kappaB (NF B) p65, TERT and ER antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Materials and Methods

Materials
Cell culture and experimental conditions
PC12 rat pheochromocytoma cells transfected with the full-length human ER gene (PCER) or with vector DNA alone (PCCON) were a kind gift from Dr Monica M Oblinger (Chicago Medical School, North Chicago, IL, USA). The cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 100 units/ml penicillin G sodium, and 100 µg/ml streptomycin sulfate in the presence of 5% CO 2 at 37 C.
Apoptosis assay
Five thousand cells/well were placed into extracellular matrix-coated chamber slides in DMEM with 10% FBS, and then starved for 48 h in phenol red-free DMEM with 10% charcoal-stripped serum (CSS). After starvation, some cells were treated with various materials. Apoptosis was assessed by terminal deoxynucleotidyl transferasemediated dUTP nick end-labeling (TUNEL) staining using an Apoptosis In Situ Detection kit (Wako, Osaka, Japan), and the cells undergoing programmed cell death were counted in five separate fields per experiment.
Stretch PCR assay
For quantitative analysis of telomerase activity, stretch PCR assays were performed using the Telochaser system according to the manufacturer's protocol (Toyobo, Tokyo, Japan) as described previously (Kyo et al. 1999 , Kawagoe et al. 2003 , Kimura et al. 2004 . Briefly, we resuspended the cell pellets in cell lysis buffer so that an aliquot of 20 µl corresponded to 25 000 cells. After incubation for 60 min at 37 C, the DNA product was isolated and 26 cycles of PCR amplification were performed at 95 C for 30 s, at 68 C for 30 s and at 72 C for 45 s. The PCR products were electrophoresed on a 7% polyacrylamide gel and visualized with SYBR Green I Nucleic Acid Gel Stain (FMC BioProducts, Rockland, ME, USA). To monitor the efficiency of PCR amplification, 10 ng of an internal control consisting of phage DNA (Toyobo) together with 50 pmol of specific primers (Toyobo) were added to the PCR mixture per reaction. Band intensity was measured using NIH Image software developed at the US National Institute of Health and available on the internet at http:/ rsb.info.nih.gov/nih-image/.
RT-PCR analysis
Total cellular RNA was isolated using Tri-Reagent (Molecular Research Center, Inc., Cinncinati, OH, USA). The expression of rat TERT (rTERT) mRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were analyzed by semiquantitative RT-PCR amplification as described previously (Kyo et al. 1999) . Briefly, rTERT mRNAs were amplified using the primer pair 5 -GGCTCTTCTTCTACCGTAAG-3 and 5 -TGATGCTTGACCTCCTCTTG-3 . cDNA was synthesized from 1 µg RNA using an RNA PCR kit version 2 (TaKaRa, Ohtsu, Japan) with random primers. Serially diluted cDNA reverse-transcribed from 1 µg RNA was first amplified by RT-PCR to generate standard curves. The correlation between band intensity and dose of cDNA template was linear under the conditions described below. Typically, 2 µl aliquots of the reverse-transcribed cDNA were amplified by 29 cycles of PCR in 50 µl of 1 buffer (10 mM Tris-HCl (pH 8·3), 2·5 mM MgCl 2 , and 50 mM KCl) containing 1 mM each of dATP, dCTP, dGTP and dTTP, 2·5 units Taq DNA polymerase (TaKaRa), and each specific primer at 0·2 µM. Each cycle consisted of denaturation at 94 C for 60 s, annealing at 52 C for 60 s, and extension at 72 C for 90 s. PCR products were resolved by electrophoresis in a 1% agarose gel. The efficiency of cDNA synthesis from each sample was estimated by PCR with GAPDH-specific primers as described previously (Kyo et al. 1999) .
Western blot analysis
Cells were incubated in phenol red-free medium without serum for 48 h and then treated with various agents. They were then washed twice with phosphate-buffered saline and lysed in ice-cold HNTG buffer (50 mM HEPES, pH 7·5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1·5 mM MgCl 2 , 1 mM EDTA, 10 mM sodium pyrophosphate, 100 µM sodium orthovanadate, 100 mM NaF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride) (Mabuchi et al. 2002) . The lysates were centrifuged at 12 000 × g at 4 C for 15 min, and the protein concentrations of the supernatants were determined using the Bio-Rad protein assay reagent. Equal amounts of proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. Blocking was done in 5% skim milk in 1× Tris-buffered saline (TBS). Western blot analyses were performed with various specific primary antibodies. For detection of phosphorylated rTERT or association of rTERT with Akt, and the association of TERT with NF B, cell lysates were prepared using HNTG buffer. Lysates were incubated with anti-TERT antibody overnight and then immunoprecipitated for 2 h with protein A-Sepharose. Immune complexes were washed with ice-cold HNTG buffer, electrophoresed, and analyzed by immunoblotting with anti-phospho-Akt substrate antibody or anti-NF B p65 antibody. Immunoreacted bands in the immunoblots were visualized with horseradish peroxidase-coupled goat antirabbit or anti-mouse immunoglobulin using the enhanced chemiluminescence Western blotting system.
Statistics
Statistical analysis was performed by Student's t-test, and P<0·01 was considered significant. Data are expressed as the mean S.E.
Results
Both E 2 and raloxifene attenuate A -induced apoptosis
Since it has been reported that both estrogen (Bonnefont et al. 1998 ) and raloxifene (Nilsen et al. 1998) induce neurite outgrowth in ER-positive PC12 cells, we examined whether estrogen or raloxifene attenuates A -induced apoptosis using ER -transfected PC12 cells (PCER), whose parent cells are known to express ER but not ER (Bonnefont et al. 1998 , Gollapudi & Oblinger 2001 . The MCF-7 human breast cancer cell line was used as a positive control to detect ER . Western blotting analysis confirmed that PCER and MCF-7 cells expressed ER , while PCCON cells (cells transfected with vector alone) did not (Fig. 1A) . Cultured cells were grown in the presence of 10% CSS (Fig. 1B, upper panel) or 10% CSS + A (Fig. 1B, lower panel) with or without 10 8 M E 2 or 10 8 M raloxifene. Cultured cells were stained by the TUNEL method. Apoptotic cells were stained brown (Fig. 1B) , and were counted under a light microscope. Although A induced apoptosis in both PCCON and PCER cells, 10 8 M E 2 or 10 8 M raloxifene significantly inhibited the A -induced apoptosis in PCER cells treated with A , but not in PCCON cells treated with A (Fig. 1B, C) . These data suggest the possibility that both E 2 and raloxifene might attenuate the A -induced apoptosis in the presence of ER .
Both E 2 and raloxifene induce telomerase activity
Since TERT has been reported to protect neurons against A -induced apoptosis (Zhu et al. 2000) , we examined the effects of estrogen and raloxifene on telomerase activity. A -treated PCCON and PCER cells were treated with 10 8 M E 2 or 10 8 M raloxifene and were subjected to quantitative stretch PCR assays to assess the telomerase activity. It appeared that both E 2 and raloxifene induced the telomerase activity in PCER cells treated with A , but not in PCCON cells treated with A (Fig. 2) .
The effects of E 2 and raloxifene on the expression of TERT
Since the telomerase activity is known to be modulated by regulation of the level of telomerase catalytic subunit (TERT) at both the transcriptional and posttranscriptional levels, semiquantitative RT-PCR assays were performed to examine whether the activation of telomerase by estrogen or by raloxifene was due to up-regulation of the expression of TERT mRNA. Although treatment of MCF-7 cells with 10 8 M E 2 for 24 h induced the expression of TERT mRNA (Fig. 3A and B, lanes 7 and 8), treatment of PCCON (Fig. 3A) or PCER (Fig. 3B ) cells with 10 8 M E 2 or 10 8 M raloxifene in the presence or absence of A for 24 h seemed to exhibit no change in the expression of TERT mRNA, suggesting the possibility that these agents might induce the telomerase activity by a mechanism without influencing the transcriptional level, as shown previously for the cytokine-induced telomerase activity (Akiyama et al. 2002) .
Both E 2 and raloxifene induce the phosphorylation of Akt
Telomerase activity may also be regulated by posttranslational modifications of the enzyme. It has been reported that the region surrounding Ser-824 in hTERT conforms to a consensus sequence for phosphorylation by Akt, and that Akt kinase enhances human telomerase activity through phosphorylation of hTERT (Kang et al. 1999) . In addition, it was reported that estrogen protects against A -induced neurotoxicity by activation of Akt (Zhang et al. 2001) . Therefore, we next examined whether E 2 or raloxifene induces the phosphorylation of Akt. The cells were treated with E 2 or raloxifene for various times, and the cell lysates were resolved by SDS-PAGE and then subjected to Western blotting with anti-phospho-Akt antibody or anti-Akt antibody. Although E 2 and raloxifene did not affect the expression of Akt (Fig. 4A, B , bottom panel), they induced transient phosphorylation of Akt (Fig. 4A , B, top and middle panels).
Both E 2 and raloxifene induce telomerase activity via the phosphatidylinositol 3-kinase (PI3K)/Akt cascade
To examine whether the PI3K/Akt cascade is involved in the E 2 -and raloxifene-induced telomerase activation, A -treated PCER cells were treated with 10 8 M E 2 or 10 8 M raloxifene in the presence or absence of LY294002 and subjected to quantitative stretch PCR assays to assess the telomerase activity. LY294002 apparently attenuated both E 2 -and raloxifene-induced telomerase activation in A -treated PCER cells (Fig. 5) , suggesting the possibility that the PI3K/Akt cascade might be involved in the induction of telomerase activity by E 2 and raloxifene.
Both E 2 and raloxifene induce the phosphorylation of TERT at a putative Akt phosphorylation site
We examined whether E 2 or raloxifene induces the phosphorylation of TERT at a putative Akt phosphorylation site. Cells were treated with E 2 or raloxifene for various times and then used to prepare lysates that were immunoprecipitated with anti-TERT antibody and then subjected to Western blotting with anti-phospho-Akt substrate antibody or anti-TERT antibody (Fig. 6) . The increase in TERT phosphorylation induced by E 2 or raloxifene at a putative Akt phosphorylation site reached a plateau at 30 min and declined thereafter (Fig. 6, top and middle panels). The anti-TERT Western blot analysis showed equal precipitation of TERT protein in the various lysates (Fig. 6, bottom panel) .
Both E 2 and raloxifene induce the association of NF B with TERT
One possible mechanism for the post-translational modification of telomerase is via the interaction of TERT with accessory proteins. Recently, NF B was reported to be a post-translational modifier of telomerase that functions by controlling the intracellular localization of hTERT (Akiyama et al. 2003) . Therefore, we examined whether E 2 or raloxifene induces the association of NF B p65 with TERT. Cells were treated with E 2 or raloxifene for the indicated times and used to prepare cell lysates that were immunoprecipitated with anti-TERT antibody and then subjected to Western blotting with anti-NF B p65 antibody or anti-TERT antibody. E 2 and raloxifene did not affect the expression of hTERT (Fig. 7, bottom panel) , but 8 M E 2 (lanes 2 and 5) or 10 8 M raloxifene (lanes 3 and 6) for 24 h in the presence (lanes 4-6) or absence (lanes 1-3) of LY294002 and were subjected to quantitative stretch PCR assays to assess the telomerase activity.
the association of TERT with NF B p65 was upregulated by E 2 and raloxifene (Fig. 7 , top and middle panels).
Discussion
One of the two novel findings in this study was that raloxifene, like estrogen, protects neurons against Ainduced apoptosis by activation of Akt in PC12 cells transfected with ER . Correlative studies with raloxifene and Akt in the brain have not been performed, but we previously demonstrated that raloxifene rapidly activates Akt in vascular endothelial cells (Hisamoto et al. 2001b) , suggesting that a similar regulation in the brain by raloxifene is possible. Another finding we made here was that the up-regulation of telomerase activity induced by both estrogen and raloxifene via phosphorylation of hTERT at a putative Akt phosphorylation site and association of hTERT with NF B might be involved in their neuroprotective functions. Thus, Akt may have an important role in the neuroprotective functions of both estrogen and raloxifene (Fig. 8) .
The Women's Health Initiative Memory Study (WHIMS) has recently shown that estrogen plus progestin therapy did not prevent cognitive impairment and did not improve cognitive function . It was also reported that raloxifene treatment for 3 years did not affect overall cognitive scores in postmenopausal women with osteoporosis (Yaffe et al. 2001) . Since the participants in these studies were elderly postmenopausal women aged 65 years or older, it remains possible that either estrogen or raloxifene may be useful in younger postmenopausal women who are in the latent pathogenetic stages of AD before extensive damage to the integrity of the brain occurs.
We examined the mechanism of the estrogen-and raloxifene-induced post-transcriptional up-regulation of telomerase activity in this study. Phosphorylation of TERT protein is one mechanism of telomerase activation. Telomerase activity in human breast cancer cells is markedly inhibited by treatment with protein phosphatase 2A (Li et al. 1997) . Some protein kinases, such as Akt kinase and protein kinase C, have been reported to mediate the phosphorylation of TERT protein, leading to telomerase activation (Li et al. 1998 , Kang et al. 1999 . The region surrounding Ser-824 in hTERT conforms to a consensus sequence for phosphorylation by Akt (Kang et al. 1999) . In the present study, both estrogen and raloxifene-induced telomerase activity seems to be dependent on the phosphorylation of TERT at a putative Akt phosphorylation site (Fig. 5) and independent of the amount of TERT expression (Fig. 3) , as shown previously in the case of cytokine-induced telomerase activity (Akiyama et al. 2002) .
Moreover, NF B p65 was recently reported to be a post-translational modifier of telomerase that functions by controlling the intracellular localization of hTERT (Akiyama et al. 2003 , Kawagoe et al. 2003 . We found that the association of TERT with NF B p65 was upregulated by both E 2 and raloxifene in PCER cells (Fig. 7) . This result leads us to speculate that NF B p65 in neural cells may play a pivotal role in regulating telomerase activity by modulating the nuclear translocation of TERT. As we have demonstrated that nuclear translocation of TERT is necessary for E 2 -induced telomerase activity in MCF-7 cells (Kawagoe et al. 2003) , we are also examining whether E 2 and raloxifene induce nuclear translocation of TERT in PCER cells.
Two ER isoforms, ER and ER , are expressed in the adult brain. Which ER is involved in the neuroprotection by estrogen and raloxifene? To elucidate the individual ER subtype involved in E 2 -mediated neuroprotection in vivo, specific ER knockout mice models have been used, including ER knockout mice (ERKO) and ER knockout mice ( ERKO). E 2 failed to protect the brain of ovariectomized ERKO mice (Dubal et al. 2001) . In contrast, E 2 protected the brain of ovariectomized ERKO mice in a manner similar to that observed in ovariectomized wild-type mice (Dubal et al. 2001) . Moreover, we have shown that estrogen and raloxifene induce the activation of Akt via ER , but not ER , in vascular endothelial (Hisamoto et al. 2001a,b) and human ovarian cancer (Mabuchi et al. 2004) cells. In addition, all membrane forms described to date are related to ER , and not to ER (Flouriot et al. 2000 , Norfleet et al. 2000 , Marquez & Pietras 2001 . However, further studies are needed to clarify the role(s) of the individual ER isoforms in estrogen-or raloxifene-mediated neuroprotection.
Induction of telomerase activity via Akt might not be the only cascade involved in the neuroprotection by estrogen and raloxifene against A -induced apoptosis. Much of the cellular damage caused by A can be attributed to dysregulation of calcium homeostasis. Because Bcl-2 plays a key role in mitochondrial Ca 2+ regulation (Murphy et al. 1996) , E 2 -induced attenuation of the increased mitochondrial sequestration of Ca 2+ in response to excitotoxic glutamate is reported to be correlated with an increase in the expression of the anti-apoptotic gene bcl-2 (Nilsen & Brinton 2003) , which is also increased by E 2 in vivo (Alkayed et al. 2001) and in vitro (Singer et al. 1998) . These findings suggest the involvement of a genomic mechanism of the actions for estrogen in its neuroprotective effects.
